{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CR+%2B+placebo&page=2", "query": { "intervention": "CR + placebo", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 98, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CR+%2B+placebo&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CR+%2B+placebo&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T00:16:31.921Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02799758", "title": "Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperlipidemia", "Dyslipidemia" ], "interventions": [ { "name": "NK-104-CR", "type": "DRUG" }, { "name": "Livalo® IR", "type": "DRUG" }, { "name": "Placebo (for NK-104-CR)", "type": "DRUG" }, { "name": "Placebo (for Livalo® IR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kowa Research Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2016-02", "completion_date": "2017-11", "has_results": false, "last_update_posted_date": "2021-05-10", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 69, "location_summary": "Foley, Alabama • Huntsville, Alabama • Montgomery, Alabama + 66 more", "locations": [ { "city": "Foley", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02799758" }, { "nct_id": "NCT05889182", "title": "A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "Upadacitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1328, "start_date": "2023-06-21", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 87, "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fountain Hills", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05889182" }, { "nct_id": "NCT00255528", "title": "Dose Ranging, Safety and Tolerability of TOPROL-XL® Extended-Release Tablets in Hypertensive Pediatric Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "metoprolol succinate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "6 Years to 16 Years" }, "enrollment_count": 144, "start_date": "2002-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-03-20", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 30, "location_summary": "Little Rock, Arkansas • Bellflower, California • Beverly Hills, California + 27 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00255528" }, { "nct_id": "NCT00202449", "title": "Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stress Disorders, Post-Traumatic", "Sleep Disorders" ], "interventions": [ { "name": "prazosin", "type": "DRUG" }, { "name": "paroxetine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seattle Institute for Biomedical and Clinical Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 59, "start_date": "2004-07", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2018-07-10", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Fort Lewis, Washington", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lewis", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00202449" }, { "nct_id": "NCT04066491", "title": "Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Biliary Tract Cancer", "Cholangiocarcinoma", "Gallbladder Cancer" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 309, "start_date": "2019-09-20", "completion_date": "2022-11-10", "has_results": true, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 12, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 9 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04066491" }, { "nct_id": "NCT01159652", "title": "Hypnotic Medications and Memory: Effect of Drug Exposure During the Night", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Sleep", "Memory" ], "interventions": [ { "name": "zaleplon", "type": "DRUG" }, { "name": "zolpidem extended release", "type": "DRUG" }, { "name": "bedtime placebo", "type": "DRUG" }, { "name": "middle of the night placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Luke's Hospital, Chesterfield, Missouri", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 26, "start_date": "2010-10", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2014-08-26", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 1, "location_summary": "Chesterfield, Missouri", "locations": [ { "city": "Chesterfield", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01159652" }, { "nct_id": "NCT03670953", "title": "A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease (Disorder)" ], "interventions": [ { "name": "IR CD-LD", "type": "DRUG" }, { "name": "IPX203 ER CD-LD", "type": "DRUG" }, { "name": "Placebo Matching IPX203", "type": "OTHER" }, { "name": "Placebo Matching IR CD-LD", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Impax Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 630, "start_date": "2018-11-06", "completion_date": "2021-06-15", "has_results": true, "last_update_posted_date": "2023-02-09", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 56, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03670953" }, { "nct_id": "NCT01988883", "title": "Modafinil and Cognitive Function in POTS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Postural Tachycardia Syndrome" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Modafinil", "type": "DRUG" }, { "name": "Propranolol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 20, "start_date": "2014-10", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-15", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01988883" }, { "nct_id": "NCT00027703", "title": "Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Mesothelioma", "Epithelial Mesothelioma", "Localized Malignant Mesothelioma", "Recurrent Malignant Mesothelioma", "Sarcomatous Mesothelioma" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2001-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-02-11", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00027703" }, { "nct_id": "NCT00308451", "title": "A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nutrition 21, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2003-11", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2006-03-29", "last_synced_at": "2026-10-02T00:16:31.921Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00308451" } ] }